Network pharmacological research of Qishen Yiqi Dropping Pills in the treatment of heart failure with preserved ejection fraction
ZHANG Jie1 LAI Runmin1 JU Jianqing2 CHEN Zhuo3▲ XU Hao2▲
1.Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China;
3.Department of Hematology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing 100091, China
Abstract：Objective To explore the potential active components and mechanisms of Qishen Yiqi Dropping Pills on the treatment of heart failure with preserved ejection fraction (HFpEF) through network pharmacology-based techniques. Methods The active components and target information of Astragalus propinquus Schischkin, Salvia miltiorrhiza Bunge, Ranax Notoginseng（Burk.）F. H. Chen, and Dalbergiae Odoriferae T. Chen were collected by BATMAN-TCM platform. Genecards database and PALM-IST platform was used to collect target genes related to HFpEF. Search date was March 4, 2019. Drug-active components-target network was constructed and visualized by Cytoscape 3.2.1. Topological characteristic of the nodes in the network was analyzed using network analyzer. Target genes interaction was analyzed by STRING database while gene ontology (GO) and pathways enrichment were analyzed by Metascape database. Results A total of 95 potential active components and 262 potential target genes of HFpEF were obtained from Qishen Yiqi Dropping Pills. Gene enrichment analysis showed that Qishen Yiqi Dropping Pills played a role in treatment of HFpEF by regulating biological process including inflammatory response, oxidative stress, myocardial fibrosis and apoptosis. Conclusion This study preliminarily discussed potential active components and mechanism of Qishen Yiqi Dropping Pills on the treatment of HFpEF on a network pharmacological basis, revealing the multi-component, multi-target and multi-channel integrated regulating effect, and provids theoretical information for further experimental research.
[1] Ponikowski P，Voors AA，Anker SD，et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure：The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology （ESC）. Developed with the special contribution of the Heart Failure Association （HFA） of the ESC [J]. Eur J Heart Fail，2016，18（8）：891-975.
[2] Shiga T，Suzuki A，Haruta S，et al. Clinical characteristics of hospitalized heart failure patients with preserved，mid‐range，and reduced ejection fractions in Japan [J]. ESC Heart Fail，2019，6（3）：475-486.
[3] Parikh KS，Sharma K，Fiuzat M，et al. Heart failure with preserved ejection fraction expert panel report：current controversies and implications for clinical trials [J]. JACC Heart Fail，2018，6（8）：619-632.
[4] 刘晶，徐浩.从气血理论探讨射血分数保留心力衰竭的中医药防治[J].中西医结合心脑血管病杂志，2017，15（17）：2210-2213.
[5] 刘晶，徐浩.益气活血法治疗射血分数保留心力衰竭气虚血瘀证临床疗效和安全性的Meta分析[J].中西医结合心脑血管病杂志，2018，16（11）：1476-1480.
[6] 曹士强.曲美他嗪联合芪参益气滴丸治疗左室射血分数保留型心力衰竭的效果研究[J].当代医药论丛，2017，15（1）：138-139.
[7] 李欣.芪参益气滴丸联合曲美他嗪治疗左室射血分数保留心衰的临床研究[J].中西医结合心脑血管病杂志，2014，12（5）：557-559.
[8] Lam CSP，Voors AA，De Boer RA，et al. Heart failure with preserved ejection fraction：from mechanisms to therapies [J]. Eur Heart J，2018，39（30）：2780-2792.
[9] Lekavich CL，Barksdale DJ，Neelon V，et al. Heart failure preserved ejection fraction （HFpEF）：an integrated and strategic review [J]. Heart Fail Rev，2015，20（6）：643-653.
[10] 朱明丹，杜武勋，刘长玉，等.芪参益气滴丸对AMI大鼠心肌炎症因子影响的动态观察[J].时珍国医国药，2013， 24（1）：22-25.
[11] 崔佩佩，王刚，宋生有，等.芪参益气滴丸对大鼠心肌缺血Ppp3r1及Atp5d 基因表达变化的影响[J].药物评价研究，2010，33（3）：191-193.
[12] 李彦川，刘育英，陈媛媛，等.芪参益气滴丸后给药对心肌肥厚大鼠心肌纤维化的阻断作用[J].微循环学杂志，2010，20（2）：67.
[13] 李良萍，冯越，杨家虎，等.芪参益气滴丸对糖尿病心肌病大鼠心肌纤维化的影响[J].中国现代医生，2017，55（35）：32-34，38，封3.
[14] 谷丰，杨巧宁，白瑞娜，等.芪参益气滴丸治疗冠心病介入术后合并高血压患者的预后研究[J].世界中医药，2018， 13（10）：2396-2400.
[15] Zhang L，Zhang H，Li X，et al. Miltirone protects human EA. hy926 endothelial cells from oxidized low-density lipoprotein-derived oxidative stress via a heme oxygenase-1 and MAPK/Nrf2 dependent pathway [J]. Phytomedicine，2016，23（14）：1806-1813.
[16] Liaudet L，Feihl F，Rosselet A，et al. Beneficial effects of L-canavanine，a selective inhibitor of inducible nitric oxide synthase，during rodent endotoxaemia [J]. Clin Sci，1996，90（5）：369-377.
[17] Riehle C，Bauersachs J. Key inflammatory mechanisms underlying heart failure [J]. Herz，2019，44（2）：96-106.
[18] Paulus WJ，Tsch?觟pe C. A novel paradigm for heart failure with preserved ejection fraction：comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation [J]. J Am Coll Cardiol，2013，62（4）：263-271.
[19] Warbrick I，Rabkin SW. Hypoxia-inducible factor 1-alpha（HIF-1α）as a factor mediating the relationship between obesity and heart failure with preserved ejection fraction [J]. Obes Rev，2019，20（5）：701-712.
[20] McHugh K，DeVore AD，Wu J，et al. Heart Failure with Preserved Ejection Fraction and Diabetes：JACC State-of-the-Art Review [J]. J Am Coll Cardiol，2019，73（5）：602-611.
[21] Bhatia RS，Tu JV，Lee DS，et al. Outcome of heart failure with preserved ejection fraction in a population-based study [J]. N Engl J Med，2006，355（3）：260-269.
[22] Echouffo-Tcheugui JB，Xu H，DeVore AD，et al. Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure：findings from Get With The Guidelines-Heart Failure registry [J]. Am Heart J，2016，182：9-20.
[23] Greene SJ，Gheorghiade M，Borlaug BA，et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction[J]. J Am Heart Assoc，2013，2（6）：e000536.
2020, Vol. 17 
京公网安备 11010502046598号